00950 LEE'S PHARM
- 1.320
- 0.0000.00%
LEE'S PHARM News
LEE'S PHARM: Supplemental Announcement - Inside Information - Land Resumption
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
LEE'S PHARM: Inside Information - Land Resumption
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
LEE'S PHARM: Voluntary Announcement - Potential Acceptance Notice of Investigational New Drug Application of Recombinant Anfibatide Injection
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
LEE'S PHARM: Notification Letter and Reply Form to Non-Registered Shareholders - Notice of Publication of Interim Report
LEE'S PHARM: Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of Interim Report
LEE'S PHARM: Interm Report 2024
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
LEE'S PHARM: Interim Dividend for the Six Months Ended 30 June 2024
LEE'S PHARM: Interim Results for the Six Months Ended 30 June 2024
LEE'S PHARM: Notice of Board Meeting
LEE'S PHARM: Positive Profit Alert
LEE'S PHARM: Voluntary Announcement - The First Patient in Hong Kong Receives AU409, a Novel Drug Product Manufactured by Zhaoke Guangzhou, in a Phase I Liver Cancer Clinical Trial
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
LEE'S PHARM: List of Directors and their Roles and Functions
LEE'S PHARM: Appointment of Non-Executive Director
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
No Data